Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen

C. M. Vachon; J. N. Ingle; V. J. Suman; C. G. Scott; H. Gottardt; J. E. Olson; P. E. Goss

doi:10.1016/j.breast.2006.10.007

Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen

C. M. Vachon, J. N. Ingle, V. J. Suman, C. G. Scott, H. Gottardt, J. E. Olson, P. E. Goss

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

Breast density, a strong risk factor for breast cancer, is reduced by the anti-estrogen, tamoxifen (TAM). We examined whether aromatase inhibitor (AI) therapy results in further reductions in breast density among women completing 5 years of TAM. Among a sample of women with early-onset breast cancer who were randomized to letrozole (LET)(n=56) or placebo (PLAC)(n=48) after 5 years of TAM, we examine the change in percent density at 9-15 months as well as a per-year change in PD by treatment group. There was no difference in the adjusted mean change (-1.0%, LET; -0.3%, PLAC (P=0.58)) or the percentage change (-2.7%, LET; -3.0%, PLAC (P=0.96)) in PD between treatment groups at 9-15 months. Results were similar for longitudinal change (-0.68% per year, LET; -0.12% per year, PLAC (P=0.23)). Breast density does not appear to be a clinically relevant biomarker in women who already have low PD following 5 years of TAM. Crown

Original language	English (US)
Pages (from-to)	204-210
Number of pages	7
Journal	Breast
Volume	16
Issue number	2
DOIs	https://doi.org/10.1016/j.breast.2006.10.007
State	Published - Apr 2007

Keywords

Aromatase inhibitors
Breast density
Mammographic density

ASJC Scopus subject areas

Surgery
Oncology
Cancer Research

Access to Document

10.1016/j.breast.2006.10.007

Cite this

@article{793d972c17104e0b9adccc45b40fc53a,

title = "Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen",

abstract = "Breast density, a strong risk factor for breast cancer, is reduced by the anti-estrogen, tamoxifen (TAM). We examined whether aromatase inhibitor (AI) therapy results in further reductions in breast density among women completing 5 years of TAM. Among a sample of women with early-onset breast cancer who were randomized to letrozole (LET)(n=56) or placebo (PLAC)(n=48) after 5 years of TAM, we examine the change in percent density at 9-15 months as well as a per-year change in PD by treatment group. There was no difference in the adjusted mean change (-1.0%, LET; -0.3%, PLAC (P=0.58)) or the percentage change (-2.7%, LET; -3.0%, PLAC (P=0.96)) in PD between treatment groups at 9-15 months. Results were similar for longitudinal change (-0.68% per year, LET; -0.12% per year, PLAC (P=0.23)). Breast density does not appear to be a clinically relevant biomarker in women who already have low PD following 5 years of TAM. Crown",

keywords = "Aromatase inhibitors, Breast density, Mammographic density",

author = "Vachon, {C. M.} and Ingle, {J. N.} and Suman, {V. J.} and Scott, {C. G.} and H. Gottardt and Olson, {J. E.} and Goss, {P. E.}",

note = "Funding Information: The authors wish to thank Ms. Fang-Fang Wu for her estimation of breast density. This project was supported in part by a Breast SPORE grant from the National Cancer Institute, National Institutes of Health, P50 CA116201. Honoraria less than $10,000 to Dr. Ingle from Novartis, maker of Letrozole.",

year = "2007",

month = apr,

doi = "10.1016/j.breast.2006.10.007",

language = "English (US)",

volume = "16",

pages = "204--210",

journal = "Breast",

issn = "0960-9776",

publisher = "Churchill Livingstone",

number = "2",

}

TY - JOUR

T1 - Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen

AU - Vachon, C. M.

AU - Ingle, J. N.

AU - Suman, V. J.

AU - Scott, C. G.

AU - Gottardt, H.

AU - Olson, J. E.

AU - Goss, P. E.

N1 - Funding Information: The authors wish to thank Ms. Fang-Fang Wu for her estimation of breast density. This project was supported in part by a Breast SPORE grant from the National Cancer Institute, National Institutes of Health, P50 CA116201. Honoraria less than $10,000 to Dr. Ingle from Novartis, maker of Letrozole.

PY - 2007/4

Y1 - 2007/4

N2 - Breast density, a strong risk factor for breast cancer, is reduced by the anti-estrogen, tamoxifen (TAM). We examined whether aromatase inhibitor (AI) therapy results in further reductions in breast density among women completing 5 years of TAM. Among a sample of women with early-onset breast cancer who were randomized to letrozole (LET)(n=56) or placebo (PLAC)(n=48) after 5 years of TAM, we examine the change in percent density at 9-15 months as well as a per-year change in PD by treatment group. There was no difference in the adjusted mean change (-1.0%, LET; -0.3%, PLAC (P=0.58)) or the percentage change (-2.7%, LET; -3.0%, PLAC (P=0.96)) in PD between treatment groups at 9-15 months. Results were similar for longitudinal change (-0.68% per year, LET; -0.12% per year, PLAC (P=0.23)). Breast density does not appear to be a clinically relevant biomarker in women who already have low PD following 5 years of TAM. Crown

AB - Breast density, a strong risk factor for breast cancer, is reduced by the anti-estrogen, tamoxifen (TAM). We examined whether aromatase inhibitor (AI) therapy results in further reductions in breast density among women completing 5 years of TAM. Among a sample of women with early-onset breast cancer who were randomized to letrozole (LET)(n=56) or placebo (PLAC)(n=48) after 5 years of TAM, we examine the change in percent density at 9-15 months as well as a per-year change in PD by treatment group. There was no difference in the adjusted mean change (-1.0%, LET; -0.3%, PLAC (P=0.58)) or the percentage change (-2.7%, LET; -3.0%, PLAC (P=0.96)) in PD between treatment groups at 9-15 months. Results were similar for longitudinal change (-0.68% per year, LET; -0.12% per year, PLAC (P=0.23)). Breast density does not appear to be a clinically relevant biomarker in women who already have low PD following 5 years of TAM. Crown

KW - Aromatase inhibitors

KW - Breast density

KW - Mammographic density

UR - http://www.scopus.com/inward/record.url?scp=33947689213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947689213&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2006.10.007

DO - 10.1016/j.breast.2006.10.007

M3 - Article

C2 - 17145182

AN - SCOPUS:33947689213

SN - 0960-9776

VL - 16

SP - 204

EP - 210

JO - Breast

JF - Breast

IS - 2

ER -

Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this